Related Experiment Videos
Rise of defibrillation energy requirement under carvedilol therapy
J Melichercik1, M Goepfrich, T Breidenbach
1Department of Cardiology, Heart Center Lahr/Baden, Lahr, Germany. jur.mel@heart-lahr.com
Insights
Carvedilol, a beta-blocker, may increase the energy needed for internal defibrillation in ICD patients. This finding highlights potential risks of combining carvedilol with implantable cardioverter-defibrillators.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Implantable cardioverter-defibrillators (ICDs) are crucial for managing life-threatening arrhythmias.
- Carvedilol, a nonselective beta-blocker with alpha-1 blocking activity, is frequently used alongside ICDs.
- Managing concomitant antiarrhythmic therapy remains a significant challenge in ICD patients.
Observation:
- This case study focuses on a patient receiving an ICD who was also prescribed carvedilol.
- The study observed the interaction between carvedilol and the electrical therapy delivered by the ICD.
Findings:
- Carvedilol administration was associated with an increased energy requirement for internal defibrillation.
- This suggests a potential pharmacodynamic interaction affecting defibrillation efficacy.
Implications:
- Clinicians should consider the potential impact of carvedilol on defibrillation thresholds in ICD patients.
- Further research is warranted to elucidate the mechanisms and clinical significance of this interaction.
- This finding may influence treatment strategies for patients requiring both ICDs and carvedilol therapy.
Abstract:
Carvedilol, a nonselective beta 1-, beta 2-adrenoreceptor blocking agent with alpha 1-adrenoreceptor blocking activity, is often prescribed as an adjunctive pharmacological therapy in patients who received an ICD. Despite the new ICD technology, concomitant antiarrhythmic therapy still represents the most important concern in patients with an ICD. As illustrated by this case, carvedilol may also increase the energy requirement for internal defibrillation.